{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:45:40Z","timestamp":1788486340759,"version":"build-2803163510"},"reference-count":56,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T00:00:00Z","timestamp":1703894400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Victorian State Government through the Operational Infrastructure Support (OIS) Program","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"name":"1Day Sooner","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["104848\/Z\/14\/Z"],"award-info":[{"award-number":["104848\/Z\/14\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT203132\/Z\/16\/Z"],"award-info":[{"award-number":["WT203132\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Ethics"],"accepted":{"date-parts":[[2023,9,28]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>\n                    We extend recent conversation about the ethics of human challenge trials to tuberculosis (TB). TB challenge studies could accelerate vaccine development, but ethical concerns regarding risks to trial participants and third parties have been a limiting factor. We analyse the expected social value and risks of different challenge models, concluding that if a TB challenge trial has between a 10% and a 50% chance of leading to the authorisation and near-universal delivery of a more effective vaccine 3\u20135\u2009years earlier, then the trial would save between 26\u2009400 and 1\u2009100\u2009000 lives over the next 10 years. We also identify five important ethical considerations that differentiate TB from recent human challenge trials: an exceptionally high disease burden with no highly effective vaccine; heightened third party risk following the trial, and, partly for that reason, uniquely stringent biosafety requirements for the trial; risks associated with best available TB treatments; and difficulties with TB disease detection. We argue that there is good reason to consider conducting challenge trials with attenuated strains like Bacillus Calmette-Gu\u00e9rin or attenuated\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    .\n                  <\/jats:p>","DOI":"10.1136\/jme-2023-109234","type":"journal-article","created":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T13:20:23Z","timestamp":1703942423000},"page":"251-260","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Exploring the ethics of tuberculosis human challenge models"],"prefix":"10.1136","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7258-5824","authenticated-orcid":false,"given":"Abie","family":"Rohrig","sequence":"first","affiliation":[{"name":"Columbia University, New York, New York, USA"},{"name":"1Day Sooner, Baltimore, Maryland, USA"},{"name":"Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Morrison","sequence":"additional","affiliation":[{"name":"1Day Sooner, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavriel","family":"Kleinwaks","sequence":"additional","affiliation":[{"name":"1Day Sooner, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Pugh","sequence":"additional","affiliation":[{"name":"Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McShane","sequence":"additional","affiliation":[{"name":"Jenner Institute, University of Oxford Nuffield Department of Medicine, Oxford, Oxfordshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1691-6403","authenticated-orcid":false,"given":"Julian","family":"Savulescu","sequence":"additional","affiliation":[{"name":"Oxford Uehiro Centre for Practical Ethics, University of Oxford, Oxford, UK"},{"name":"Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore"},{"name":"Biomedical Research Group, Murdoch Childrens Research Institute, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,12,30]]},"reference":[{"key":"2026032002101331000_52.4.251.1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fmed.2018.00297","article-title":"Controlled human infections as a tool to reduce uncertainty in clinical vaccine development","volume":"5","author":"Roestenberg","year":"2018","journal-title":"Front Med"},{"key":"2026032002101331000_52.4.251.2","unstructured":"Expert Committee on Biological Standardization . Human challenge trials for vaccine development: regulatory considerations. World Health Organization, 2020."},{"key":"2026032002101331000_52.4.251.3","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(22)00359-7","article-title":"WHO\u2019s global tuberculosis report 2022","volume":"4","author":"Bagcchi","year":"2023","journal-title":"Lancet Microbe"},{"key":"2026032002101331000_52.4.251.4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g4643","article-title":"Effect of BCG vaccination against mycobacterium tuberculosis infection in children: systematic review and meta-analysis","volume":"349","author":"Roy","year":"2014","journal-title":"BMJ"},{"key":"2026032002101331000_52.4.251.5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12014","article-title":"Association of BCG vaccination in childhood with subsequent cancer diagnoses: a 60-year follow-up of a clinical trial","volume":"2","author":"Usher","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2026032002101331000_52.4.251.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909953"},{"key":"2026032002101331000_52.4.251.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714021"},{"key":"2026032002101331000_52.4.251.8","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S0140-6736(05)67145-0","article-title":"Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial","volume":"366","author":"Rodrigues","year":"2005","journal-title":"The Lancet"},{"key":"2026032002101331000_52.4.251.9","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1324303"},{"key":"2026032002101331000_52.4.251.10","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_554_18"},{"key":"2026032002101331000_52.4.251.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2020.101429"},{"key":"2026032002101331000_52.4.251.12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103993","article-title":"Tuberculosis vaccines in the era of COVID-19 - what is taking us so long?","volume":"79","author":"Dockrell","year":"2022","journal-title":"EBioMedicine"},{"key":"2026032002101331000_52.4.251.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.20.2701"},{"key":"2026032002101331000_52.4.251.14","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1076"},{"key":"2026032002101331000_52.4.251.15","unstructured":"World Health Organization . WHO guidance on the ethical conduct of controlled human infection studies. 2021."},{"key":"2026032002101331000_52.4.251.16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/bioe.12794","article-title":"Judging the social value of controlled human infection studies","volume":"34","author":"Rid","year":"2020","journal-title":"Bioethics"},{"key":"2026032002101331000_52.4.251.17","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-12-980","article-title":"Tuberculosis and poverty: the contribution of patient costs in sub-Saharan Africa--a systematic review","volume":"12","author":"Barter","year":"2012","journal-title":"BMC Public Health"},{"key":"2026032002101331000_52.4.251.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60570-0"},{"key":"2026032002101331000_52.4.251.19","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1164\/rccm.201912-2408ED","article-title":"Controlled human infection models: is it really feasible to give people tuberculosis?","volume":"201","author":"McShane","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032002101331000_52.4.251.20","doi-asserted-by":"crossref","unstructured":"Clark RA , Portnoy A , Weerasuriya CK , et al . The potential health and economic impacts of new tuberculosis vaccines under varying delivery strategies in Delhi and Gujarat, India: a modelling study. medRxiv 2023:2023.09.27.23296211. doi:10.1101\/2023.09.27.23296211","DOI":"10.1101\/2023.09.27.23296211"},{"key":"2026032002101331000_52.4.251.21","unstructured":"Centers for Disease Control and Prevention . Fact sheets. 2023. Available: https:\/\/www.cdc.gov\/tb\/publications\/factsheets\/general\/tb.htm [Accessed 28 Apr 2023]."},{"key":"2026032002101331000_52.4.251.22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4046\/trd.2017.0052","article-title":"Treatment of latent tuberculosis infection and its clinical efficacy","volume":"81","author":"Kim","year":"2018","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"2026032002101331000_52.4.251.23","unstructured":"TB Alert . Treatment - TB alert. 2015. Available: https:\/\/www.tbalert.org\/about-tb\/what-is-tb\/treatment\/"},{"key":"2026032002101331000_52.4.251.24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020755","article-title":"Assessing tuberculosis case fatality ratio: a meta-analysis","volume":"6","author":"Straetemans","year":"2011","journal-title":"PLoS One"},{"key":"2026032002101331000_52.4.251.25","article-title":"Acute and fatal isoniazid-induced hepatotoxicity: a case report and review of the literature","volume":"2016","author":"Kabbara","year":"2016","journal-title":"Case Rep Infect Dis"},{"key":"2026032002101331000_52.4.251.26","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30309-3"},{"key":"2026032002101331000_52.4.251.27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10346-6","article-title":"Antibiotic treatment for tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed","volume":"7","author":"Wipperman","year":"2017","journal-title":"Sci Rep"},{"key":"2026032002101331000_52.4.251.28","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir951"},{"key":"2026032002101331000_52.4.251.29","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv482"},{"key":"2026032002101331000_52.4.251.30","doi-asserted-by":"crossref","unstructured":"Skorupski J , ed. The Routledge companion to ethics. Routledge, 2010. doi:10.4324\/9780203850701","DOI":"10.4324\/9780203850701"},{"key":"2026032002101331000_52.4.251.31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/eahr.500056","article-title":"Why challenge trials of SARS\u2010CoV\u20102 vaccines could be ethical despite risk of severe adverse events","volume":"42","author":"Eyal","year":"2020","journal-title":"Ethics Hum Res"},{"key":"2026032002101331000_52.4.251.32","doi-asserted-by":"publisher","DOI":"10.1136\/jme.2008.026062"},{"key":"2026032002101331000_52.4.251.33","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2634"},{"key":"2026032002101331000_52.4.251.34","first-page":"101","article-title":"Chances and risks in living donor liver transplantation","volume":"105","author":"Walter","year":"2008","journal-title":"Dtsch Arztebl Int"},{"key":"2026032002101331000_52.4.251.35","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2021-107229"},{"key":"2026032002101331000_52.4.251.36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2021189117"},{"key":"2026032002101331000_52.4.251.37","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.vaccine.2020.11.072","article-title":"Broad cross-national public support for accelerated COVID-19 vaccine trial designs","volume":"39","author":"Broockman","year":"2021","journal-title":"Vaccine"},{"key":"2026032002101331000_52.4.251.38","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2020-107109"},{"key":"2026032002101331000_52.4.251.39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207522","article-title":"Questioning the long-term stability of the additive model in comorbid CTD+ADHD - the transition from childhood to adulthood","volume":"13","author":"M\u00fcller","year":"2018","journal-title":"PLoS One"},{"key":"2026032002101331000_52.4.251.40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/15265161.2013.851578","article-title":"What should be disclosed to research participants","volume":"13","author":"Wendler","year":"2013","journal-title":"Am J Bioeth"},{"key":"2026032002101331000_52.4.251.41","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2020-106501"},{"key":"2026032002101331000_52.4.251.42","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2020-106901"},{"key":"2026032002101331000_52.4.251.43","unstructured":"Wertheimer A . Exploitation. Princeton University Press, 2022."},{"key":"2026032002101331000_52.4.251.44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/15265161.2020.1854368","article-title":"Promoting ethical payment in human infection challenge studies","volume":"21","author":"Lynch","year":"2021","journal-title":"Am J Bioeth"},{"key":"2026032002101331000_52.4.251.45","doi-asserted-by":"publisher","DOI":"10.1111\/dewb.12011"},{"key":"2026032002101331000_52.4.251.46","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1093\/infdis\/jiz163","article-title":"How to address the risk of HIV transmission in remission studies with treatment interruption: the low-hanging fruit approach","volume":"220","author":"Eyal","year":"2019","journal-title":"J Infect Dis"},{"key":"2026032002101331000_52.4.251.47","unstructured":"Who.int . Global health Observatory | by category | BCG - immunization coverage estimates by WHO region. 2021."},{"key":"2026032002101331000_52.4.251.48","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/21645515.2015.1134407","article-title":"A review of clinical models for the evaluation of human TB vaccines","volume":"12","author":"O\u2019Shea","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2026032002101331000_52.4.251.49","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1580OC"},{"key":"2026032002101331000_52.4.251.50","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268818001760"},{"key":"2026032002101331000_52.4.251.51","doi-asserted-by":"crossref","unstructured":"Vally Hassan . What\u2019s most likely to kill you? Measuring how deadly our daily activities are. The Conversation 2017. Available: https:\/\/theconversation.com\/whats-most-likely-to-kill-you-measuring-how-deadly-our-daily-activities-are-72505","DOI":"10.64628\/AA.p6efnycyw"},{"key":"2026032002101331000_52.4.251.52","unstructured":"National Kidney Foundation . The big ask, the big give. 2017. Available: https:\/\/www.kidney.org\/transplantation\/livingdonors\/risks-of-surgery"},{"key":"2026032002101331000_52.4.251.53","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjx004"},{"key":"2026032002101331000_52.4.251.54","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/risa.13726","article-title":"Exploring risks of human challenge trials for COVID-19","volume":"41","author":"Manheim","year":"2021","journal-title":"Risk Anal"},{"key":"2026032002101331000_52.4.251.55","unstructured":"Shah SK , Kimmelman J , Lyerly AD , et al . Ethical considerations for Zika virus human challenge trials. National Institute of Allergy and Infectious Diseases, 2017."},{"key":"2026032002101331000_52.4.251.56","doi-asserted-by":"crossref","unstructured":"Chi PC , Owino EA , Jao I , et al . Understanding the benefits and burdens associated with a malaria human infection study in Kenya: experiences of study volunteers and other stakeholders. In Review [Preprint] 2021. doi:10.21203\/rs.3.rs-143195\/v2","DOI":"10.21203\/rs.3.rs-143195\/v2"}],"container-title":["Journal of Medical Ethics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jme-2023-109234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T09:11:37Z","timestamp":1773997897000},"score":1,"resource":{"primary":{"URL":"https:\/\/jme.bmj.com\/lookup\/doi\/10.1136\/jme-2023-109234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,30]]},"references-count":56,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,3,20]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/jme-2023-109234"],"URL":"https:\/\/doi.org\/10.1136\/jme-2023-109234","relation":{},"ISSN":["0306-6800","1473-4257"],"issn-type":[{"value":"0306-6800","type":"print"},{"value":"1473-4257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,30]]}}}